Name: PRELUDE THERAPEUTICS INC (PRLD) Stock
Brand: PRELUDE THERAPEUTICS INC
Rating: 5.5 (3 reviews)

PRLD Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Chartmill

Prelude Therapeutics Inc. (NASDAQ:PRLD) Beats Q3 2025 Earnings Estimates and Extends Cash Runway

10 days ago - By: Chartmill - Mentions: EVOK RUBI CHAC IHRT ...

In today's session, these stocks are experiencing unusual volume.

2 days ago - By: Benzinga - Mentions: ALKS ENGN IMMP MLSS ...

12 Health Care Stocks Moving In Thursday's After-Market Session

3 days ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

3 days ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

3 days ago - By: The Schall Law Firm

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm

11 days ago - By: Benzinga - Mentions: ACET RIGL TEM AKTX ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

11 days ago - By: Chartmill - Mentions: TGE HTZ DENN KFRC ...

Which stocks are experiencing notable movement on Tuesday?

11 days ago - By: Chartmill - Mentions: FGL RUBI TACO MODD ...

On Tuesday, there are stocks with unusual volume. Let's take a look.

11 days ago - By: Chartmill - Mentions: TGE HTZ DENN KFRC ...

Tuesday's session: top gainers and losers

11 days ago - By: Chartmill - Mentions: TGE PAY FORD HTZ ...

These stocks are gapping in today's session

11 days ago - By: Chartmill - Mentions: CYD HTZ DENN NSP ...

Tuesday's pre-market session: top gainers and losers

11 days ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Strategic Business Update

11 days ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Strategic Business Update

11 days ago - By: Prelude Therapeutics, Incorporated - Mentions: INCY

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

11 days ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

11 days ago - By: Chartmill - Mentions: OC SANM NSP SRPT ...

These stocks are moving in today's after hours session

12 days ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

12 days ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

a month ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

a month ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

3 months ago - By: The Motley Fool

Prelude Cuts Q2 Losses and Costs 13%

3 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

3 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

6 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

6 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

6 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

6 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

7 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

7 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

7 months ago - By: Prelude Therapeutics, Incorporated

Prelude Announces Presentations at 2025 AACR Annual Meeting

7 months ago - By: Prelude Therapeutics, Incorporated

Prelude Announces Presentations at 2025 AACR Annual Meeting

7 months ago - By: Yahoo Finance - Mentions: GOSS DAWN VIR NUVB ...

PRELUDE THERAPEUTICS INC (PRLD) Stock News

PRLD Latest News, Press Relases and Analysis

Prelude Therapeutics Inc. (NASDAQ:PRLD) Beats Q3 2025 Earnings Estimates and Extends Cash Runway

In today's session, these stocks are experiencing unusual volume.

12 Health Care Stocks Moving In Thursday's After-Market Session

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm

12 Health Care Stocks Moving In Tuesday's After-Market Session

Which stocks are experiencing notable movement on Tuesday?

On Tuesday, there are stocks with unusual volume. Let's take a look.

Tuesday's session: top gainers and losers

These stocks are gapping in today's session

Tuesday's pre-market session: top gainers and losers

Prelude Therapeutics Announces Strategic Business Update

Prelude Therapeutics Announces Strategic Business Update

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

These stocks are moving in today's after hours session

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

Prelude Cuts Q2 Losses and Costs 13%

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

Prelude Announces Presentations at 2025 AACR Annual Meeting

Prelude Announces Presentations at 2025 AACR Annual Meeting

Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple